Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The patent application describes an optimized expression system to produce a world-first fully synthetic recombinant version of PRP
-
ALISO VIEJO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational...
-
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced...
-
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancersNOUS-209 is an off-the-shelf cancer immunotherapy designed to induce...
-
RICHMOND, Ind., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Liberation Bioindustries announces its co-founders have assumed new roles in the company; originally Chief Executive Officer (CEO), Mark Warner is...
-
This high unmet need has drawn interest to novel mechanisms of action — including Propanc Biopharma’s pancreatic proenzyme formulation known as PRP.
-
NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation...
-
-- Study Results Support the use of TellDx to Personalize Cancer Care Management – -- Clinical study published in Cancer Discovery -- ANDOVER, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) -- TellBio,...
-
MONTRÉAL, 14 janv. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») (TSXV : LOVE) (OTCQX : LOVFF) (FRA : 8CB0), producteur verticalement...
-
Cannara qualified for OTCQX trading in the U.S. and will release its Q1 2026 financial results on January 26, 2026